Good morning :)
Place Order
Add to Watchlist

Laurus Labs Ltd

LAURUSLABS Share Price

628.050.18% (+1.15)

LAURUSLABS Share Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹33,785 cr, stock is ranked 230
Moderate RiskStock is 2.48x as volatile as Nifty

LAURUSLABS Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹33,785 cr, stock is ranked 230
Moderate RiskStock is 2.48x as volatile as Nifty

LAURUSLABS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
168.718.210.13%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.396.290.54%

LAURUSLABS Analyst Ratings & Forecast

Detailed Forecast 
45%
Analysts have suggested that investors can buy this stock

from 11 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

LAURUSLABS Company Profile

Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Investor Presentation

View older 

Jan 24, 2025

PDF
View Older Presentations

LAURUSLABS Similar Stocks (Peers)

Compare with peers 
PE Ratio
43.78
1Y Return
15.50%
Buy Reco %
88.24
PE Ratio
29.62
1Y Return
12.46%
Buy Reco %
72.73
PE Ratio
66.34
1Y Return
27.80%
Buy Reco %
68.00
PE Ratio
55.55
1Y Return
7.76%
Buy Reco %
81.25
PE Ratio
17.34
1Y Return
2.34%
Buy Reco %
46.67
Compare with Peers
LAURUSLABS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly

LAURUSLABS Stock Summary · January 2025

Laurus Labs demonstrated robust revenue growth in Q3 FY25, driven by strong demand in the CDMO sector, despite challenges in the ARV business, which saw a 7% decline in revenue. The company is strategically enhancing its manufacturing capabilities, particularly in complex APIs and precision fermentation, while maintaining healthy gross margins above 50%. Management remains optimistic about future growth, supported by a diverse product pipeline and significant investments in R&D and new facilities. Although the ARV segment faces short-term challenges, a solid order book and ongoing collaborations with major pharmaceutical partners position Laurus for long-term success. Overall, the outlook reflects confidence in navigating current market dynamics while capitalizing on emerging opportunities.

Key Points on Lauruslabs Stock
LAURUSLABS Stock Growth Drivers
7
  • Strong Performance in CDMO Business

    Laurus Labs has demonstrated significant achievements in its Contract Development and Manufacturing Organization (CDMO) business,

  • Healthy Financial Metrics

    The company reported strong financial results, with Q3 revenues reaching INR 1,415 crores, an 18%

LAURUSLABS Stock Challenges
7
  • Decline in ARV API Business

    Laurus Labs reported a 3% decline in their ARV API business over the past nine

  • Operational De-leverage and Margin Pressure

    The company experienced ongoing operational de-leverage, impacting margins. For Q3, EBITDA margins were reported at

LAURUSLABS Forecasts

Price

Revenue

Earnings

LAURUSLABS

Income

Balance Sheet

Cash Flow

LAURUSLABS Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 17.03%, vs industry avg of 9.04%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.05% to 1.33%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 11.35%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,781.941,937.032,085.362,308.072,837.644,837.174,950.876,046.555,067.175,308.39
Raw Materialssubtract1,033.241,031.671,088.411,267.631,629.552,455.202,414.942,752.282,533.304,397.16
Power & Fuel Costsubtract57.9666.2794.21109.37136.77157.75204.47324.10338.15
Employee Costsubtract175.46204.73238.14276.33320.77397.04469.55557.43614.85
Selling & Administrative Expensessubtract67.9792.2596.07140.99189.38239.88276.15291.01335.07
Operating & Other expensessubtract80.75102.10126.03141.61-9.3012.96148.03523.54441.96
Depreciation/Amortizationsubtract86.41105.98125.45164.19187.27205.07251.49324.08384.58421.91
Interest & Other Itemssubtract111.1199.9079.6488.1989.5968.16102.39165.17182.90210.10
Taxes & Other Itemssubtract35.3043.8669.8125.9938.34317.53256.33318.8375.8178.96
EPS0.861.813.171.774.7918.3615.4114.692.983.72
DPS0.100.300.300.300.502.002.002.000.800.80
Payout ratio0.120.170.090.170.100.110.130.140.270.22

LAURUSLABS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Apr 28PDF
Jan 28PDF
Jan 27PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 27PDF
Jan 30PDF
Oct 21PDF
Jul 27PDF
FY 2024

Annual report

PDF

Investor Presentation

Jul 27PDF
FY 2025

Annual Report Pending

Investor Presentation

Jan 24PDF
Oct 24PDF
 

LAURUSLABS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Laurus Labs Ltd210.448.210.13%
Sun Pharmaceutical Industries Ltd43.786.250.77%
Cipla Ltd29.624.550.86%
Torrent Pharmaceuticals Ltd66.3416.030.86%

LAURUSLABS Stock Price Comparison

Compare LAURUSLABS with any stock or ETF
Compare LAURUSLABS with any stock or ETF
LAURUSLABS
Loading...

LAURUSLABS Shareholdings

LAURUSLABS Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

LAURUSLABS Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

LAURUSLABS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding27.62%7.62%5.12%25.56%34.08%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

LAURUSLABS Shareholding History

SepDec '23MarJunSepDec '2424.03%25.39%25.97%25.67%26.08%25.56%

Mutual Funds Invested in LAURUSLABS

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Laurus Labs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.0167%1.17%0.01%56/87 (+1)
0.4027%4.51%1.00%7/34 (+5)
0.3844%0.57%0.36%79/137 (-6)

Compare 3-month MF holding change on Screener

LAURUSLABS Insider Trades & Bulk Stock Deals

Loading...

smallcases containing LAURUSLABS stock

Looks like this stock is not in any smallcase yet.

LAURUSLABS Events

LAURUSLABS Dividend Trend

No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

LAURUSLABS has shown inconsistent dividend trend over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.13%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.28 every year

Dividends

Corp. Actions

Announcements

Legal Orders

LAURUSLABS Upcoming Dividends

No upcoming dividends are available

LAURUSLABS Past Dividends

Cash Dividend

Ex DateEx DateNov 6, 2024

Interim
Interim | Div/Share: ₹0.40

Dividend/Share

0.40

Ex DateEx Date

Nov 6, 2024

Cash Dividend

Ex DateEx DateMay 8, 2024

Interim 2
Interim 2 | Div/Share: ₹0.40

Dividend/Share

0.40

Ex DateEx Date

May 8, 2024

Cash Dividend

Ex DateEx DateNov 2, 2023

Interim
Interim | Div/Share: ₹0.40

Dividend/Share

0.40

Ex DateEx Date

Nov 2, 2023

Cash Dividend

Ex DateEx DateMay 10, 2023

Interim 2
Interim 2 | Div/Share: ₹1.20

Dividend/Share

1.20

Ex DateEx Date

May 10, 2023

Cash Dividend

Ex DateEx DateNov 3, 2022

Interim
Interim | Div/Share: ₹0.80

Dividend/Share

0.80

Ex DateEx Date

Nov 3, 2022

LAURUSLABS Stock News & Opinions

Corporate
Laurus Labs declare Quarterly Result

Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 April 2025.Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Laurus Labs to acquire 26% stakes in Kurnool Renewables for Rs 35 cr

The strategic move will enable Laurus Labs to access 25.53 MW of renewable wind and solar energy, which aligns with regulatory requirements under Indian Electricity Laws and government policies for captive consumption of power. The investment is aimed at reducing electricity costs, ensuring a reliable green power supply, and obtaining carbon credits, thus contributing to the company's environmental, social, and governance (ESG) objectives. Kurnool Renewables is engaged in the production of renewable energy, primarily from solar and wind sources. Laurus Labs' investment will support the development of the renewable power project, which will be used for captive consumption. This acquisition is expected to provide benefits such as reduced energy costs, enhanced energy security, and increased operational stability along with potential environmental advantages. The equity shares will be subscribed at an issue price determined by Kurnool Renewables, with a total investment of up to Rs 35 crore. The payment will be made in cash in three stages: 30% within 30 days from the execution of agreements, 40% upon placing orders for major equipment, and the remaining 30% upon receipt of major equipment at the project site. The acquisition does not fall within the purview of a related party transaction. In addition, Laurus Labs' board has approved the re-appointment of V.V. Ravi Kumar as the Executive Director and Chief Financial Officer (CFO) of the company for a period of two years, effective from 1 April 2025, subject to shareholder approval. V. V. Ravi Kumar is the executive director and chief financial officer of Laurus Labs Limited, bringing over three decades of rich experience, and especially two decades in Laurus itself, in finance, strategy, and corporate leadership. A qualified cost accountant from the Institute of Cost and Works Accountants of India, he plays a pivotal role in steering Laurus Labs toward sustainable growth and excellence. As a key leader at Laurus Labs, Mr. Ravi Kumar oversees critical business functions, including finance, information technology, mergers & acquisitions, strategic alliances, human resources, etc. He does not have any inter-se relationship with other directors of the company. The board also approved the re-appointment of Dr. Satyanarayana Chava as executive director and CEO for five years, starting 1, April 2025, subject to shareholder approval. Dr. Chava, the founder and CEO of Laurus Labs, has more than 30 years of experience in the pharmaceutical industry, with around 20 years at Laurus Labs. He holds a Ph.D. in chemistry from Andhra University and has been instrumental in positioning the company as a leader in both domestic and international markets. Dr. Satyanarayana Chava is the father of Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava, executive directors of the company. Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in generic active pharmaceutical ingredients (APIs) and a major focus on anti-retroviral and oncology drugs, cardiovascular, gastro, and hepatitis C therapeutics. The company also develops and manufactures oral solid formulations and provides contract research and manufacturing services (CRAMS) to global pharma companies. The company's consolidated net profit soared 298.9% to Rs 92.30 crore in Q3 FY25 as against Rs 23.14 crore posted in Q3 FY24. Net sales jumped 18.4% YoY to Rs 1,415.05 crore in the quarter ended 31 December. The counter shed 0.76% to Rs 613.50 on the BSE. Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Board of Laurus Labs approves investment of Rs 83.30 cr in KRKA Pharma

The Board of Laurus Labs at its meeting held on 06 March 2025 has approved investment of an amount of Rs 83.30 crore in KRKA Pharma (KRKA), a joint venture of the Company. Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of Rs 86.70 crore in KRKA. Thereby, maintaining the existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs. The purpose of this investment is to acquire land and to meet initial cost of setting up of a manufacturing facility for production of finished products for the new markets, including the Indian market. This investment aligns with the company's strategic growth plans and long-term business objectives. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Laurus Labs Ltd soars 3.43%, up for third straight session

Laurus Labs Ltd rose for a third straight session today. The stock is quoting at Rs 564.2, up 3.43% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.3% on the day, quoting at 22369.85. The Sensex is at 73855.47, up 1.19%. Laurus Labs Ltd has dropped around 11.4% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has dropped around 9.06% in last one month and is currently quoting at 19820.65, up 0.98% on the day. The volume in the stock stood at 18.59 lakh shares today, compared to the daily average of 27.02 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 565.1, up 3.1% on the day. Laurus Labs Ltd is up 37.39% in last one year as compared to a 0.46% fall in NIFTY and a 4.57% fall in the Nifty Pharma index.The PE of the stock is 117.78 based on TTM earnings ending December 24.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Laurus Labs Ltd down for fifth straight session

Laurus Labs Ltd is down for a fifth straight session today. The stock is quoting at Rs 546.75, down 9.03% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.87% on the day, quoting at 22830.85. The Sensex is at 75660.79, down 0.63%.Laurus Labs Ltd has lost around 1.82% in last one month.Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has eased around 5.47% in last one month and is currently quoting at 21427.1, down 3.06% on the day. The volume in the stock stood at 48.57 lakh shares today, compared to the daily average of 44.71 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 546.25, down 9.02% on the day. Laurus Labs Ltd jumped 39.28% in last one year as compared to a 4.2% rally in NIFTY and a 11.87% spurt in the Nifty Pharma index.The PE of the stock is 129.77 based on TTM earnings ending December 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Laurus Labs Ltd gains for third straight session

Laurus Labs Ltd is up for a third straight session today. The stock is quoting at Rs 638.45, up 1.16% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.41% on the day, quoting at 23600.05. The Sensex is at 77920.62, down 0.45%. Laurus Labs Ltd has gained around 4.25% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has gained around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 18.29 lakh shares today, compared to the daily average of 42.52 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 639.8, up 1.03% on the day. Laurus Labs Ltd is up 60.15% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.The PE of the stock is 136.31 based on TTM earnings ending December 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Laurus Labs consolidated net profit rises 298.88% in the December 2024 quarter

Net profit of Laurus Labs rose 298.88% to Rs 92.30 crore in the quarter ended December 2024 as against Rs 23.14 crore during the previous quarter ended December 2023. Sales rose 18.42% to Rs 1415.05 crore in the quarter ended December 2024 as against Rs 1194.92 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1415.051194.92 18 OPM %20.1515.18 - PBDT236.77133.03 78 PBT130.6834.62 277 NP92.3023.14 299 Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Laurus Labs Ltd spurts 3.11%, gains for third straight session

Laurus Labs Ltd is up for a third straight session in a row. The stock is quoting at Rs 585.45, up 3.11% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.64% on the day, quoting at 23350.8. The Sensex is at 77182.56, up 0.74%. Laurus Labs Ltd has added around 3.42% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 1.96% in last one month and is currently quoting at 22061.7, up 0.31% on the day. The volume in the stock stood at 9.9 lakh shares today, compared to the daily average of 18.42 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 585.1, up 2.72% on the day. Laurus Labs Ltd is up 46.75% in last one year as compared to a 9.94% gain in NIFTY and a 26.31% gain in the Nifty Pharma index.The PE of the stock is 130.29 based on TTM earnings ending September 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Laurus Labs to discuss results

Laurus Labs will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Laurus Labs Ltd gains for fifth session

Laurus Labs Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 590.25, up 0.61% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.03% on the day, quoting at 23805.25. The Sensex is at 78760.73, up 0.08%. Laurus Labs Ltd has added around 2.33% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 3.28% in last one month and is currently quoting at 23008.35, up 0.77% on the day. The volume in the stock stood at 16.64 lakh shares today, compared to the daily average of 19.78 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 593.15, up 0.61% on the day. Laurus Labs Ltd is up 36.3% in last one year as compared to a 9.49% gain in NIFTY and a 37.53% gain in the Nifty Pharma index.The PE of the stock is 134.5 based on TTM earnings ending September 24.Powered by Capital Market - Live

3 months agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Laurus Labs Ltd (LAURUSLABS) today?

    The share price of LAURUSLABS as on 17th April 2025 is ₹628.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Laurus Labs Ltd (LAURUSLABS) share?

    The past returns of Laurus Labs Ltd (LAURUSLABS) share are
    • Past 1 week: 8.62%
    • Past 1 month: 7.31%
    • Past 3 months: 10.61%
    • Past 6 months: 32.18%
    • Past 1 year: 45.58%
    • Past 3 years: 4.18%
    • Past 5 years: 669.20%

  3. What are the peers or stocks similar to Laurus Labs Ltd (LAURUSLABS)?
  4. What is the dividend yield % of Laurus Labs Ltd (LAURUSLABS) share?

    The current dividend yield of Laurus Labs Ltd (LAURUSLABS) is 0.13.

  5. What is the market cap of Laurus Labs Ltd (LAURUSLABS) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Laurus Labs Ltd (LAURUSLABS) is ₹33785.84 Cr as of 17th April 2025.

  6. What is the 52 week high and low of Laurus Labs Ltd (LAURUSLABS) share?

    The 52-week high of Laurus Labs Ltd (LAURUSLABS) is ₹646.20 and the 52-week low is ₹385.45.

  7. What is the PE and PB ratio of Laurus Labs Ltd (LAURUSLABS) stock?

    The P/E (price-to-earnings) ratio of Laurus Labs Ltd (LAURUSLABS) is 210.44. The P/B (price-to-book) ratio is 8.21.

  8. Which sector does Laurus Labs Ltd (LAURUSLABS) belong to?

    Laurus Labs Ltd (LAURUSLABS) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Laurus Labs Ltd (LAURUSLABS) shares?

    You can directly buy Laurus Labs Ltd (LAURUSLABS) shares on Tickertape. Simply sign up, connect your demat account and place your order.